APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility.
APIS has deep expertise and capabilities in IVD development of molecular & immune assays for ultimate product realisation as diagnostic tests. In addition, APIS' expertise in bioinformatics and software development is offered as an agile service to our clients, to develop bespoke, end-to-end multi-OMICs solutions and platform development.
APIS has also developed a broad breast oncology product portfolio: The APIS Breast Cancer Subtyping Kit is a reproducible RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The APIS ESR1 Mutations Kit is a qPCR assay for the sensitive detection of eleven key mutations within the oestrogen receptor gene. Coming soon - the new APIS PIK3CA Mutations Kit is a qPCR assay for the sensitive detection of key mutations in the PIK3CA gene.
Company Details
- Employees
- 61
- Address
- Citylabs 1.0, Manchester,uk M13 9nq,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- apisassay.com
- Keywords
- to our clients.
- HQ
- MANCHESTER, UK
Apis Assay Technologies Ltd. Questions
Apis Assay Technologies Ltd.'s website is apisassay.com
Apis Assay Technologies Ltd.'s LinkedIn profile is https://uk.linkedin.com/company/apis-assay-technologies-ltd
Apis Assay Technologies Ltd. has
61 employees.
View email and phone details for 61
employees at Apis Assay Technologies Ltd..
Apis Assay Technologies Ltd.'s industry is
Biotechnology Research
Apis Assay Technologies Ltd.'s top competitors are
Qiagen,
Apprentify,
Genedrive,
Campfire,
Yourgene Health,
Wedo Business Finance,
Bright Money Group,
Epistem Ltd.,
Biofortuna,
Trupcr Europe.
Apis Assay Technologies Ltd.'s categories are Biotechnology Research
